SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Farnebo Marianne)
 

Sökning: WFRF:(Farnebo Marianne) > (2020-2023) > Evaluation of dyske...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005062naa a2200517 4500
001oai:DiVA.org:umu-190412
003SwePub
008211217s2022 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1904122 URI
0247 a https://doi.org/10.3892/OL.2021.131482 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ranhem, Ceciliau Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Region Västmanland, Uppsala University, Västmanlands Hospital Västerås, Vasteras, Sweden4 aut
2451 0a Evaluation of dyskerin expression and the Cajal body protein WRAP53β as potential prognostic markers for patients with primary vaginal carcinoma
264 1b Spandidos Publications,c 2022
338 a electronic2 rdacarrier
520 a Primary vaginal cancer (PVC) is a rare gynae- cological malignancy, which, at present, lacks appropriate biomarkers for prognosis. The proteins dyskerin and WD repeat containing antisense to TP53 (WRAP53β), both of which exert their functions in the telomerase holoenzyme complex, have been shown to be upregulated in different cancer types. These proteins have also been proposed as prognostic markers in some types of cancer. The aim of the present study was to examine the expression patterns of dyskerin and WRAP53β in patients with PVC. Moreover, as part of a search for effective biomarkers to evaluate prog- nosis in PVC, the expression of these two proteins and their potential association with clinical variables and survival were also evaluated. The expression of dyskerin and WRAP53β was assessed in PVC tumour samples from 68 patients using immunohistochemistry. The majority of tumour samples showed low and moderate expression levels of dyskerin. Upregulation of dyskerin in tumour samples was signifi- cantly associated with a shorter survival time and a poorer cancer-specific survival rate. WRAP53β was also expressed in most of the cells but was not significantly associated with clinical variables or survival. This study demonstrates that upregulation of dyskerin is significantly associated with poor prognosis. Thus, dyskerin may serve as a promising prognostic marker and a potential putative therapeutic target in PVC.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Biomarker
653 a Cajal body
653 a Dyskerin
653 a Primary vaginal carcinoma
653 a Prognosis
653 a Survival
653 a WRAP53β
653 a onkologi
653 a Oncology
7001 a Larsson, Gabriella Lillsundeu School of Health and Medical Sciences, Örebro University, Campus USÖ, Örebro, Sweden; Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden4 aut
7001 a Lindqvist, David,c Docent,d 1981-u Umeå universitet,Onkologi4 aut0 (Swepub:umu)dali0066
7001 a Sorbe, Bengtu Department of Oncology, Örebro University Hospital, Sweden4 aut
7001 a Karlsson, Mats G.u School of Medical Sciences, Örebro University, Örebro, Sweden4 aut
7001 a Farnebo, Marianneu Department of Bioscience and Nutrition, Karolinska Institutet, Stockholm, Sweden; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Hellman, Kristinau Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Kovaleska, Larysau R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kiev, Ukraine4 aut
7001 a Kashuba, Elenau R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kiev, Ukraine; Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden4 aut
7001 a Andersson, Soniau Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden4 aut
7102 a Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Region Västmanland, Uppsala University, Västmanlands Hospital Västerås, Vasteras, Swedenb School of Health and Medical Sciences, Örebro University, Campus USÖ, Örebro, Sweden; Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden4 org
7730 t Oncology Lettersd : Spandidos Publicationsg 23:1q 23:1x 1792-1074x 1792-1082
8564 u https://doi.org/10.3892/OL.2021.13148y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1621256/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-190412
8564 8u https://doi.org/10.3892/OL.2021.13148

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy